PF-4693627 是一种有效的,口服生物可利用的,选择性的微粒体前列腺素E合酶 (mPGES-1) 抑制剂 (IC50=3 nM),可用于骨关节炎和类风湿关节炎等的研究。
生物活性 | PF-4693627 is a potent, selective and orally bioavailablemicrosomalprostaglandin E synthase-1 (mPGES-1) inhibitor (IC50=3 nM) for the treatment of inflammation caused by osteoarthritis (OA) and rheumatoid arthritis (RA)[1]. |
IC50& Target | |
体外研究 (In Vitro) | PF-4693627 also inhibits mPGES-1 with IC50s of 180 and 6 nM in HWB-1483 and human fetal fibroblast, respectively[1]. PF-4693627 shows high activity in lipopolysaccharide (LPS) stimulated human whole blood (HWB) cell assay (IC50=109 nM)[1].
|
体内研究 (In Vivo) | PF-4693627 (10 mg/kg; orally) inhibits 63% of PGE2 production relative to vehicle control in Guinea pig carrageenan stimulated air pouch model[1]. PF-4693627 (1.0 mg/kg; i.v.) shows good bioavailability (59%) and modest half life (t1/2=3.7 h) in Sprague-Dawley rats[1].
Animal Model: | Guinea pig with carrageenan stimulated air pouch inflammation model[1] | Dosage: | 10 mg/kg | Administration: | Administered orally | Result: | 63% PGE2 inhibition. |
Animal Model: | Sprague-Dawley rats[1]. | Dosage: | 1.0 mg/kg (Pharmacokinetic Analysis) | Administration: | Administered i.v. | Result: | Clearance (CL), volume of distribution (Vdss), t1/2, mean residence time (MRT) and bioavailability (F) is 12 mL/min/kg, 3.0 L/kg, 3.7 h, 4.42 h, 59%, respectively. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 100 mg/mL(199.03 mM;Need ultrasonic) 配制储备液 1 mM | 1.9903 mL | 9.9516 mL | 19.9033 mL | 5 mM | 0.3981 mL | 1.9903 mL | 3.9807 mL | 10 mM | 0.1990 mL | 0.9952 mL | 1.9903 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 |